OncoMatch/Clinical Trials/NCT05178693
Lutathera and ASTX727 in Neuroendocrine Tumours
Is NCT05178693 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ASTX727 for neuroendocrine tumors.
Treatment: ASTX727 — Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use \[68Ga\]-DOTA-TATE PET to image epigenetic modification of the receptor locus.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Biomarker criteria
Required: MKI67 Ki67 < 55% (< 55%)
Ki67 < 55%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: somatostatin analogue — first line
Progression or intolerance to first line therapy including somatostatin analogues
Cannot have received: Lutathera or ASTX727
Previous treatment with either study medication
Cannot have received: radiation therapy
Exception: palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS allowed with 1-week washout
Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify